Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report details a blocklisting application submitted to the Financial Services Authority and the London Stock Exchange Plc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding share issuance rather than a financial performance report.
Material Changes
The material change reported is the application to admit 30,000,000 ordinary shares of 25p each to the Official List. These shares are reserved under block listings for issuance pursuant to employee share schemes.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The primary contingency noted is the successful admission of the reserved shares to the Official List, after which they will rank pari passu with existing ordinary shares.
Important Facts for Investors
- Total of 30,000,000 ordinary shares are being reserved for issuance.
- Shares are allocated to two schemes: 15,000,000 for the GlaxoSmithKline Share Option Plan - ADS and 15,000,000 for the GlaxoSmithKline Share Option Plan - Ordinary shares.
- The application was signed by Victoria Whyte, Company Secretary, on January 20, 2012.
- No financial performance data is included in this specific filing.